Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Licenses Gencarta Database to Japanese Pharma Kyowa-Hakko

NEW YORK, July 17 – Compugen licensed its Gencarta database of annotated genomic, transcription, and proteomic data to the Japanese pharmaceutical company Kyowa-Hakko Kogyo, the companies announced Tuesday.

Financial details of the deal were not disclosed.

“We chose Compugen’s Gencarta database and mining tools because of its exceptional transcriptome analysis,” Seiga Itoh, senior executive officer, drug discovery division of Tokyo-based Kyowa-Hakko said in a statement. “We expect that the integration of Compugen's proprietary and comprehensive gene and protein database into our research will significantly advance our drug discovery and development processes.”

Compugen released Gencarta in March. The database uses Compugen’s Leads algorithm to provide annotation of the transcription factors that bridge genes and proteins. Leads takes into account alternative splicing, in which exons, or coding regions, on one gene can combine in different ways to form different proteins.

Avalon Pharmaceuticals of Gaithersburg, MD, licensed Gencarta in April.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.